Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-iodobenzovesamicol
- Development stage
- Unknown
- Lead developer
- University of Michigan
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
5-Iodobenzovesamicol (IBVM) is a radiolabeled cholinergic neuron marker used primarily in research and clinical imaging. It acts as a high-affinity ligand for the vesicular acetylcholine transporter (VAChT), allowing visualization of cholinergic nerve terminals in the brain using single-photon emission computed tomography (SPECT) or positron emission tomography (PET). Radiolabeled forms such as [^123I]IBVM and [^125I]IBVM are utilized for animal studies and human brain imaging to assess cholinergic function, particularly in neurodegenerative diseases like Alzheimer's disease. The compound is highly specific for VAChT and does not significantly bind to other neurotransmitter systems. Its mechanism enables non-invasive mapping of cholinergic deficits associated with cognitive disorders[1][3].
- Other names
- IBVM(-)-5-iodobenzovesamicoliodobenzovesamicol
02
Targets
SIGMAR1 (Sigma non-opioid intracellular receptor 1)TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))SLC18A3 (Vesicular acetylcholine transporter)
Beyond the preview
Go deeper on 5-iodobenzovesamicol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-iodobenzovesamicol.